Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand to Report Third Quarter Financial Results on November 9, 2021 By: Ligand Pharmaceuticals Incorporated via Business Wire October 26, 2021 at 16:01 PM EDT Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss third quarter 2021 financial results and provide general business updates Date: Tuesday, November 9, 2021 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call: Dial (833) 540-1167 within the U.S. Dial (929) 517-0358 outside the U.S. Conference ID is 5486177 Webcast: Live and replay webcast of the call are available here. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory affairs and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND. View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006038/en/Contacts Ligand Pharmaceuticals Incorporated Simon Latimer investors@ligand.com (858) 550-7766 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss bvoss@lhai.com (310) 691-7100 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Ligand to Report Third Quarter Financial Results on November 9, 2021 By: Ligand Pharmaceuticals Incorporated via Business Wire October 26, 2021 at 16:01 PM EDT Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss third quarter 2021 financial results and provide general business updates Date: Tuesday, November 9, 2021 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call: Dial (833) 540-1167 within the U.S. Dial (929) 517-0358 outside the U.S. Conference ID is 5486177 Webcast: Live and replay webcast of the call are available here. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory affairs and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND. View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006038/en/Contacts Ligand Pharmaceuticals Incorporated Simon Latimer investors@ligand.com (858) 550-7766 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss bvoss@lhai.com (310) 691-7100
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conference call to discuss third quarter 2021 financial results and provide general business updates Date: Tuesday, November 9, 2021 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Conference Call: Dial (833) 540-1167 within the U.S. Dial (929) 517-0358 outside the U.S. Conference ID is 5486177 Webcast: Live and replay webcast of the call are available here. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand’s business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory affairs and commercialization) to ultimately generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on Twitter @Ligand_LGND. View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006038/en/
Ligand Pharmaceuticals Incorporated Simon Latimer investors@ligand.com (858) 550-7766 Twitter: @Ligand_LGND LHA Investor Relations Bruce Voss bvoss@lhai.com (310) 691-7100
